Amy Hobeika

5.2k total citations · 1 hit paper
90 papers, 4.2k citations indexed

About

Amy Hobeika is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Amy Hobeika has authored 90 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Immunology, 51 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Amy Hobeika's work include Immunotherapy and Immune Responses (55 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Immune Cell Function and Interaction (22 papers). Amy Hobeika is often cited by papers focused on Immunotherapy and Immune Responses (55 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Immune Cell Function and Interaction (22 papers). Amy Hobeika collaborates with scholars based in United States, China and United Kingdom. Amy Hobeika's co-authors include H. Kim Lyerly, Michael A. Morse, Timothy M. Clay, Takuya Osada, Howard M. Johnson, Donna Niedzwiecki, Alain Delcayre, Jean‐Bernard Le Pecq, Prem S. Subramaniam and Paul J. Mosca and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Amy Hobeika

86 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

2005 917 citations Michael A. Morse, Takuya Osada et al. Journal of Translational Medicine profile →

Peers

Countries citing papers authored by Amy Hobeika

Since Specialization

Citations

This map shows the geographic impact of Amy Hobeika's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Hobeika with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Hobeika more than expected).

Fields of papers citing papers by Amy Hobeika

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Hobeika. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Hobeika. The network helps show where Amy Hobeika may publish in the future.

Co-authorship network of co-authors of Amy Hobeika

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Hobeika. A scholar is included among the top collaborators of Amy Hobeika based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Hobeika. Amy Hobeika is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer 2024 ·Human Vaccines & Immunotherapeutics ·(unknown), (unknown), Gangjun Lei, (unknown), Xiaoyi Yang, Tao Wang, (unknown), (unknown), Amy Hobeika, (unknown), (unknown), Michael A. Morse, H. Kim Lyerly, Erika J. Crosby, Zachary C. Hartman	6
2	Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma 2022 ·Nature Communications ·Clare A. Rebbeck, Jian Xian, Susanne Bornelöv, Joseph Geradts, Amy Hobeika, Heather Geiger, (unknown), (unknown), (unknown), Nicolas Robine, H. Kim Lyerly, Gregory J. Hannon	16
3	Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation 2021 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Shuo Wang, Fang Tong, Xiaoguang Qiu, Xiaoli Wang, Xinna Zhou, Michael A. Morse, Amy Hobeika, Wanshui Wu, Huabing Yang, Jun Ren, H. Kim Lyerly	5
4	Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients 2019 ·Journal of Thrombosis and Thrombolysis ·Xiaoli Wang, Shuo Wang, Michael A. Morse, Ni Jiang, Yanjie Zhao, (unknown), Lei Zhou, Hongyan Huang, Xinna Zhou, Amy Hobeika, Jun Ren, H. Kim Lyerly	8
5	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study 2019 ·Clinical Cancer Research ·Erika J. Crosby, William R. Gwin, Kimberly Blackwell, P. Kelly Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, Terry Hyslop, Sungjin Kim, André Rogatko, Veronica Lubkov, Joshua C. Snyder, Takuya Osada, Amy Hobeika, Michael A. Morse, H. Kim Lyerly, Zachary C. Hartman	54
6	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study 2018 ·Clinical Cancer Research ·Guoliang Qiao, Xiaoli Wang, Lei Zhou, Xinna Zhou, (unknown), Shuo Wang, Lei Zhao, Michael A. Morse, Amy Hobeika, (unknown), Xin Yi, Xuefeng Xia, Jun Ren, H. Kim Lyerly	52
7	Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS) 2018 ·Clinical & Translational Oncology ·Yanhua Zhao, (unknown), (unknown), Yang Song, Xin Zhou, Ni Jiang, Lei Zhou, Hongyan Huang, (unknown), (unknown), Amy Hobeika, Jun Ren, H. Kim Lyerly	38
8	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers 2018 ·Breast Cancer Research ·Takuya Osada, Zachary C. Hartman, Jun-Ping Wei, Gangjun Lei, Amy Hobeika, William R. Gwin, Márcio A. Diniz, Neil L. Spector, Timothy M. Clay, Wei Chen, Michael A. Morse, H. Kim Lyerly	15
9	Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study 2017 ·Clinical Cancer Research ·Ni Jiang, Guoliang Qiao, Xiaoli Wang, Michael A. Morse, William R. Gwin, Lei Zhou, (unknown), Yanjie Zhao, Feng Chen, Xinna Zhou, (unknown), Amy Hobeika, Xin Yi, Xuefeng Xia, Yanfang Guan, (unknown), Jun Ren, H. Kim Lyerly	64
10	In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior 2017 ·Clinical Cancer Research ·Takuya Osada, (unknown), William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, H. Kim Lyerly	14
11	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine 2017 ·Cancer Chemotherapy and Pharmacology ·Xinna Zhou, Guoliang Qiao, Xiaoli Wang, Qingkun Song, Michael A. Morse, Amy Hobeika, William R. Gwin, Jun Ren, H. Kim Lyerly	8
12	Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion 2012 ·Journal of Translational Medicine ·Erika Hamilton, Kimberly Blackwell, Amy Hobeika, Timothy M. Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frédéric Lehmann, Neil L. Spector, Jun-Ping Wei, Takuya Osada, H. Kim Lyerly	78
13	Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients 2011 ·Clinical Cancer Research ·Michael A. Morse, Robert Chapman, John D. Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, (unknown), (unknown), Venky Ramakrishna, Laura Vitale, Biwei Zhao, Stephen A. Butler, Amy Hobeika, Takuya Osada, Thomas A. Davis, Timothy Clay, H. Kim Lyerly	112
14	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity 2010 ·Clinical Cancer Research ·Zachary C. Hartman, Jun-Ping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, (unknown), (unknown), Dong‐Wan Kim, Wenle Xia, Neil L. Spector, Jeffrey R. Marks, William T. Barry, Amy Hobeika, Gayathri R. Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, Timothy M. Clay	21
15	Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo 2009 ·International Journal of Cancer ·Michael A. Morse, Jun-Ping Wei, Zachary C. Hartman, Wenle Xia, (unknown), Gangjun Lei, William T. Barry, Takuya Osada, Amy Hobeika, (unknown), Haixiang Jiang, Gayathri R. Devi, Wei Chen, Neil L. Spector, Andrea Amalfitano, H. Kim Lyerly, Timothy M. Clay	19
16	Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody 2009 ·British Journal of Cancer ·Takuya Osada, David S. Hsu, Scott A. Hammond, Amy Hobeika, Gayathri R. Devi, Timothy M. Clay, H. Kim Lyerly, Michael A. Morse	61
17	Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease 2008 ·Cytotherapy ·Amy Hobeika, Takuya Osada, Delila Serra, (unknown), Kimberly E. Hanson, (unknown), Donna Niedzwiecki, Nelson J. Chao, David A. Rizzieri, H. Kim Lyerly, Timothy Clay, Michael A. Morse	7
18	NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity 2005 ·Cancer Immunology Immunotherapy ·Takuya Osada, Timothy Clay, Amy Hobeika, H. Kim Lyerly, Michael A. Morse	55
19	Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. 2000 ·PubMed ·Scott L. Kominsky, Amy Hobeika, (unknown), Barbara A. Torres, Howard M. Johnson	50
20	IFNγ inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1 1998 ·Oncogene ·Scott L. Kominsky, Howard M. Johnson, (unknown), Taishi Tanabe, Amy Hobeika, Prem S. Subramaniam, Barbara A. Torres	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact